Tempus announces a collaboration with verastem to develop cdx for first-ever fda-approved kras-mutant recurrent low-grade serous ovarian cancer combination treatment

Chicago--(business wire)--tempus ai, inc. (nasdaq: tem), a technology company leading the adoption of ai to advance precision medicine and patient care, today announced a collaboration to develop a companion diagnostic (cdx) test with verastem oncology (nasdaq: vstm), a biopharmaceutical company committed to advancing new medicines for patients with ras/mapk pathway-driven cancers. tempus completed confirmatory testing in verastem's phase 2 ramp-201 clinical trial, which evaluated the combinati.
TEM Ratings Summary
TEM Quant Ranking